Mydecine Innovations Group Files Final Prospectus in Connection with Bought Deal Offering of Units

Author's Avatar
Feb 09, 2021
Article's Main Image

Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, is pleased to announce that, in connection with its bought deal offering (the “Offering”) previously announced on January 14, 2021, it has filed its final short form prospectus (the “Prospectus”) with the securities commissions or similar authorities in each province of Canada, other than Quebéc.